Unicycive Therapeutics Inc

Unicycive’s recent RSU awards reveal executive confidence, hint at future growth, and signal strategic alignment with clinical milestones, reimbursement trends, and digital‑health integration.

Unicycive’s recent RSU grants to CFO Townsend John and execs show board confidence in its pipeline, yet the share drop, negative P/E, and mixed sentiment urge cautious assessment.

Unicycive insiders boost confidence: Laumas Sandeep’s RSU grant of 126,300 shares—worth $1.04 million—signals strong board faith in its hyperphosphatemia therapies. Read on.